Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicaid | 19 | 2026 | 368 | 4.430 |
Why?
|
| Nursing Homes | 13 | 2025 | 674 | 3.440 |
Why?
|
| Atrial Fibrillation | 8 | 2025 | 869 | 2.810 |
Why?
|
| Anticoagulants | 10 | 2025 | 520 | 2.800 |
Why?
|
| Accountable Care Organizations | 10 | 2026 | 74 | 2.740 |
Why?
|
| Homes for the Aged | 3 | 2025 | 161 | 1.920 |
Why?
|
| Medicare | 11 | 2025 | 615 | 1.710 |
Why?
|
| United States | 37 | 2026 | 8051 | 1.670 |
Why?
|
| Dementia | 3 | 2025 | 272 | 1.490 |
Why?
|
| Stroke | 5 | 2023 | 1205 | 1.440 |
Why?
|
| Health Care Costs | 5 | 2026 | 224 | 1.430 |
Why?
|
| Ambulatory Care | 2 | 2025 | 316 | 1.270 |
Why?
|
| Hospitalization | 9 | 2026 | 1385 | 1.220 |
Why?
|
| Hospice Care | 3 | 2025 | 74 | 1.160 |
Why?
|
| Food Assistance | 2 | 2025 | 22 | 1.100 |
Why?
|
| Hospices | 3 | 2025 | 39 | 1.060 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 2679 | 1.060 |
Why?
|
| Aged | 26 | 2026 | 14840 | 1.040 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 759 | 1.010 |
Why?
|
| Memantine | 2 | 2024 | 22 | 1.010 |
Why?
|
| Warfarin | 3 | 2025 | 124 | 0.910 |
Why?
|
| Massachusetts | 12 | 2026 | 2137 | 0.910 |
Why?
|
| Humans | 57 | 2026 | 64778 | 0.900 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 256 | 0.900 |
Why?
|
| Nootropic Agents | 1 | 2025 | 13 | 0.900 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 5565 | 0.900 |
Why?
|
| Atrial Flutter | 1 | 2025 | 33 | 0.900 |
Why?
|
| Nutritional Support | 1 | 2025 | 12 | 0.890 |
Why?
|
| Emergency Service, Hospital | 6 | 2026 | 1122 | 0.870 |
Why?
|
| Psychotropic Drugs | 1 | 2025 | 81 | 0.860 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 80 | 0.830 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2021 | 15 | 0.810 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 40 | 0.790 |
Why?
|
| Inappropriate Prescribing | 2 | 2021 | 68 | 0.770 |
Why?
|
| Male | 31 | 2026 | 30812 | 0.750 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.740 |
Why?
|
| Female | 31 | 2026 | 33765 | 0.720 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 705 | 0.690 |
Why?
|
| Medicare Part C | 1 | 2021 | 14 | 0.670 |
Why?
|
| Administration, Oral | 4 | 2024 | 371 | 0.660 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 406 | 0.650 |
Why?
|
| Mental Disorders | 2 | 2026 | 811 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2026 | 489 | 0.640 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 141 | 0.640 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 302 | 0.580 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.580 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.580 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 293 | 0.570 |
Why?
|
| Health Equity | 3 | 2025 | 51 | 0.570 |
Why?
|
| Italy | 6 | 2021 | 69 | 0.560 |
Why?
|
| Brain Ischemia | 2 | 2019 | 418 | 0.550 |
Why?
|
| Metformin | 1 | 2019 | 75 | 0.540 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.540 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 11 | 0.530 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 165 | 0.530 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 50 | 0.510 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 225 | 0.490 |
Why?
|
| Middle Aged | 16 | 2026 | 18112 | 0.480 |
Why?
|
| Meals | 2 | 2026 | 27 | 0.480 |
Why?
|
| Cohort Studies | 5 | 2024 | 2603 | 0.460 |
Why?
|
| General Practitioners | 1 | 2015 | 14 | 0.460 |
Why?
|
| Hemorrhage | 3 | 2024 | 278 | 0.440 |
Why?
|
| Drug Utilization | 3 | 2021 | 204 | 0.440 |
Why?
|
| Adult | 13 | 2026 | 17243 | 0.430 |
Why?
|
| Deprescriptions | 2 | 2025 | 27 | 0.420 |
Why?
|
| Nurses | 1 | 2015 | 107 | 0.410 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 50 | 0.400 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6811 | 0.390 |
Why?
|
| Cost of Illness | 1 | 2014 | 170 | 0.390 |
Why?
|
| Biopsy | 1 | 2014 | 454 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 734 | 0.380 |
Why?
|
| Managed Care Programs | 2 | 2025 | 86 | 0.380 |
Why?
|
| Patient Care Team | 1 | 2015 | 335 | 0.370 |
Why?
|
| Mammography | 1 | 2014 | 290 | 0.350 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 164 | 0.350 |
Why?
|
| Health Care Surveys | 2 | 2025 | 288 | 0.350 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5764 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 325 | 0.340 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 71 | 0.330 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 621 | 0.320 |
Why?
|
| Primary Health Care | 3 | 2025 | 717 | 0.320 |
Why?
|
| Quality of Life | 1 | 2017 | 1254 | 0.320 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 248 | 0.310 |
Why?
|
| Mass Screening | 1 | 2014 | 696 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 581 | 0.290 |
Why?
|
| Qualitative Research | 4 | 2026 | 740 | 0.280 |
Why?
|
| Drug Monitoring | 2 | 2022 | 202 | 0.280 |
Why?
|
| Patient Readmission | 2 | 2026 | 444 | 0.280 |
Why?
|
| Cognition Disorders | 2 | 2021 | 223 | 0.270 |
Why?
|
| Sex Factors | 3 | 2021 | 989 | 0.260 |
Why?
|
| Medicare Part D | 2 | 2025 | 36 | 0.260 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 797 | 0.250 |
Why?
|
| Age Factors | 3 | 2021 | 1580 | 0.240 |
Why?
|
| Child | 4 | 2025 | 4601 | 0.240 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 8 | 0.240 |
Why?
|
| Cost Savings | 1 | 2026 | 57 | 0.230 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 66 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1214 | 0.230 |
Why?
|
| Time Factors | 3 | 2019 | 3753 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2026 | 365 | 0.230 |
Why?
|
| Health Care Reform | 2 | 2023 | 86 | 0.230 |
Why?
|
| Social Determinants of Health | 3 | 2022 | 149 | 0.220 |
Why?
|
| Diet Therapy | 1 | 2025 | 15 | 0.220 |
Why?
|
| Research Design | 2 | 2025 | 583 | 0.220 |
Why?
|
| Residence Characteristics | 3 | 2023 | 232 | 0.220 |
Why?
|
| Nurse Administrators | 1 | 2024 | 18 | 0.220 |
Why?
|
| Prescription Drugs | 1 | 2025 | 49 | 0.220 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 45 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 174 | 0.210 |
Why?
|
| Naphthalenesulfonates | 1 | 2023 | 3 | 0.210 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2751 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 32 | 0.200 |
Why?
|
| Comorbidity | 3 | 2021 | 1115 | 0.190 |
Why?
|
| Social Responsibility | 1 | 2022 | 12 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 95 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 703 | 0.190 |
Why?
|
| Motivation | 2 | 2026 | 295 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1274 | 0.190 |
Why?
|
| Pediatrics | 1 | 2024 | 265 | 0.180 |
Why?
|
| Racism | 1 | 2023 | 91 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2025 | 741 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 768 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 63 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2021 | 33 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 140 | 0.170 |
Why?
|
| Risk Factors | 2 | 2023 | 5399 | 0.170 |
Why?
|
| Drug Repositioning | 1 | 2021 | 10 | 0.170 |
Why?
|
| Young Adult | 5 | 2025 | 4773 | 0.160 |
Why?
|
| Cognition | 1 | 2023 | 502 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 346 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2020 | 103 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.150 |
Why?
|
| Epilepsy | 1 | 2020 | 112 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.140 |
Why?
|
| Interviews as Topic | 3 | 2026 | 529 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 347 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 69 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.140 |
Why?
|
| Adolescent | 4 | 2025 | 6292 | 0.140 |
Why?
|
| Health Services Research | 1 | 2019 | 265 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 163 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 22 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 96 | 0.130 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 39 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 888 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 484 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 58 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 119 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 152 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2017 | 216 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 58 | 0.120 |
Why?
|
| Physician-Nurse Relations | 1 | 2015 | 26 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2015 | 75 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2017 | 275 | 0.110 |
Why?
|
| Medicine | 1 | 2015 | 55 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 291 | 0.110 |
Why?
|
| False Positive Reactions | 1 | 2014 | 77 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 138 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 252 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 98 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 826 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 524 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 512 | 0.100 |
Why?
|
| Poverty | 2 | 2026 | 299 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 918 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 492 | 0.080 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 75 | 0.080 |
Why?
|
| Pharmacists | 2 | 2023 | 130 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2023 | 525 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 1434 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 110 | 0.060 |
Why?
|
| Consensus | 1 | 2025 | 181 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 232 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2024 | 201 | 0.050 |
Why?
|
| Health Policy | 1 | 2025 | 192 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 74 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 219 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 94 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 83 | 0.050 |
Why?
|
| Income | 1 | 2023 | 170 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 36 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2021 | 30 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 198 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2021 | 50 | 0.040 |
Why?
|
| Palliative Care | 1 | 2023 | 245 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 847 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 229 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 291 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 458 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 593 | 0.030 |
Why?
|
| Senior Centers | 1 | 2017 | 1 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 384 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 83 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 384 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 105 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 295 | 0.030 |
Why?
|
| Health Resources | 1 | 2017 | 92 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 898 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 406 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 116 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 414 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 188 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 669 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 160 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 851 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 929 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1410 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 374 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 103 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 314 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 749 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 884 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1210 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2483 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2091 | 0.020 |
Why?
|